Actively Recruiting
Observational Study on the Effectiveness and Safety of Biological Treatments for Adults with Allergic Bronchopulmonary Aspergillosis and Severe Asthma
Led by Qianfoshan Hospital · Updated on 2026-04-17
50
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
This prospective, multicenter, observational cohort study focuses on patients with allergic bronchopulmonary aspergillosis. The aim is to evaluate the efficacy and safety of biological agents used in these patients across multiple participating centers. The study observes how biological agents perform in the treatment of allergic bronchopulmonary aspergillosis while also assessing their safety.
CONDITIONS
Brief Title
A Cohort Study of the Efficacy and Safety of Biologics in Patients With ABPA
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Meet the diagnostic criteria of allergic bronchopulmonary aspergillosis according to ISHAM guidelines (2024 revision)
- Have severe bronchial asthma as the underlying disease
- Experienced an acute asthma attack in the past year
- Blood eosinophil count is at least 150 cells per microliter
- Age 18 years or older
You will not qualify if you...
- Have chronic obstructive pulmonary disease or bronchiectasis
- Known allergy to biological agents
- Have HIV infection, active pulmonary tuberculosis, or pulmonary malignant tumor
- Have other diseases requiring long-term systemic glucocorticoids or immunosuppressants
- Are pregnant or breastfeeding
- Currently participating in other interventional clinical research
- Any other condition that would prevent study participation, such as poor adherence, predicted survival less than 1 year, or severe mental illness
Research Team
Q
Qian Qi, Dr.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here